Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Conditions
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
Interventions
- DRUG: Brentuximab Vedotin
- PROCEDURE: Hematopoietic Cell Transplantation
- BIOLOGICAL: Nivolumab
- OTHER: Quality-of-Life Assessment
- OTHER: Questionnaire Administration
Sponsor
Emory University
Collaborators